Ultimately, a subset (estimated to make up 10–60% of ganglioglioma) containing BRAF V600E/ MAPK mutations respond to MEK inhibition however effects of this treatment on other subsets harboring genetic alterations both within and outside of the MAPK pathway remains largely unknown [4]. Here, BRAF is linked to ganglioglioma.